Drug intelligence / Profile preview

nab-paclitaxel + danburstotug complex AP160

Development stage: Discontinued
Lead developer: Mayo Clinic
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

nab-paclitaxel + danburstotug complex AP160 is an investigational antibody-drug conjugate (ADC) composed of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) combined with a monoclonal antibody targeting PD-L1 (danburstotug, also known as STI-3031). Nab-paclitaxel is a protein-bound formulation of the taxane paclitaxel that acts as an antimicrotubule agent by stabilizing microtubules and inhibiting their normal dynamic reorganization during cell division. Danburstotug targets programmed death-ligand 1 (PD-L1), potentially enhancing immune-mediated tumor cell killing through checkpoint inhibition and antibody-dependent cellular cytotoxicity. The combination aims to deliver both cytotoxic chemotherapy and immunotherapy in a single agent for improved antitumor activity. The primary indication under investigation has been advanced or metastatic solid tumors[6][8].

Other names: nab-paclitaxel/danburstotug complex AP160nab-paclitaxel/STI-3031 complexAP160AP-160AP 160

Targets

CD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on nab-paclitaxel + danburstotug complex AP160.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nab-paclitaxel + danburstotug complex AP160.

Explore the full profile